

Supplementary Table S1. Progression of liver enzymes in two patients with moderate COVID-19 disease. Patients received standard of care (SoC) and 5-aminolevulinic acid phosphate with sodium ferrous citrate (5-ALA with SFC).

Patient XX01				
Study day	SoC*	5-ALA with SFC	AST (mg/L)	ALT (mg/L)
Day -3	X	-	29.2	68.3
Day -2	X	-	nm	nm
Day -1	X	-	nm	nm
Day 0	X	X	32.6	71.5
Day 1	X	X	nm	nm
Day 2	X	X	96.2	234.7
Day 3	X	X	105.9	248.0
Day 4-9	stopped	stopped	nm	nm
Day 10	-	-	41.0	107.0
Day 11-16	-	-	nm	nm
Day 17	-	-	37.6	85.1
Day 18-37	-	-	nm	nm
Day 38	-	-	24.4	49.7

* Apixiban, paracetamol, zinc, omeprazole, vitamin C, vitamin D3, dexamethasone, remdesivir, clexane, and ceftriaxone that were altered during this period.

Patient XX08				
Study day	SoC**	5-ALA with SFC	AST (mg/L)	ALT (mg/L)
Day -4	X	-	26.0	24.0
Day -3	X	-		
Day -2	X	-		
Day -1	X	-		
Day 0	X	X	63.0	90.0
Day 1	X	X		
Day 2	X	X		138.0
Day 3	X	temporarily stopped	87.0	170.0
Day 4	X	-		nm
Day 5	stopped	-	68.0	157.0
Day 6	-	X		
Day 7	-	stopped	83.0	230.0
No FU data				

** Bromhexine, azithromycin, esomeprazole, omeprazole, vitamin C, metoclopramide, sodium chloride, vitamin D, paracetamol intravenous, ceftriaxone, enoxaparin sodium, metronidazole that were altered during this period.